newsfilter
← Latest News
GlobeNewswire·

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

LAB
  • Standard BioTools announced an agreement to sell its Mass Cytometry business to Multiplex Bio, an entity led by Michael Johnson, Tom Villani, & Charles Coffman.
  • Multiplex Bio will maintain continuity of the CyTOF & Hyperion product lines, customer relationships, & the majority of the Mass Cytometry team while operating under the Standard BioTools name.
  • The transaction value is up to $10 million, consisting of a seller's note & potential milestone payments, plus a working capital loan of up to $10 million from Standard BioTools.
  • Standard BioTools received approximately $30 million from Illumina to buy out the 2026 earnout & all accrued royalty payments related to the prior SomaLogic acquisition.
  • The U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for the pending merger with Treeline Biosciences.
  • Both the Mass Cytometry sale & the Treeline merger are expected to close by the end of 2026, subject to stockholder approval & customary closing conditions.
  • Standard BioTools filed a Form S-4 registration statement with the SEC on July 20, 2026, regarding the Treeline transaction.